Last updated on 23-11-2023 by Julie Maetens
Auteurs
J. Thouvenin1,2; C. Van Marcke3; L. Decoster4; G. Raicevic; K. Punie; M. Vandenbulcke5; R. Salgado; Els Van Valckenborgh; B. Maes; S. Joris; D. Vander Steichel; K. Vranken; S. Jacobs; F. Dedeurwaerdere12; G. Martens; F. H. Devos; F. P. Duhoux; M. Rasschaert; P. Pauwels17; K. Geboes; J. Collignon20; S. Tejpar; J.-L. Canon21; M. Peeters; A. Rutten; T. Van de Mooter23; J. Vermeij; D. Schrijvers; W. Demey; W. Lybaert; J. Van Huysse27; J. Mebis; A. Awada; K. B. M. Claes; Aline Hébrant; J. Van der Meulen; B. Delafontaine30; I. Vanden Bempt; J Maetens; Maïté de Hemptinne; S. Rottey; P. Aftimos28; J. De Grève4Trefwoorden
Samenvatting:
PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinicogenomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 p…